Advances in ultra-sensitive proteomics are transforming our understanding of immune-mediated inflammatory diseases (IMIDs), enabling researchers to uncover biological signals that were previously difficult to detect and investigate.
Join leading researchers from across Europe for a scientific webinar exploring emerging biomarker insights generated using NULISA™ technology across multiple IMID indications. Through a series of research presentations and an expert panel discussion, speakers will share new findings, discuss common disease mechanisms, and explore how highly multiplexed protein profiling is advancing biomarker discovery and translational research.
Whether your work focuses on autoimmune disease, neuroinflammation, immunology, or biomarker development, this session offers an opportunity to learn from investigators actively generating new IMID datasets and applying them to important biological questions.
Attendees will have the opportunity to:
15:00-15:10 Welcome & Introduction | Overview of the webinar and the growing role of ultra-sensitive proteomics in IMID research.
15:10-15:30 Systemic Lupus Erythematosus (SLE) | Emerging biomarker insights from lupus research using NULISA technology. Chris Wincup
15:30-15:50 Neuromyelitis Optica Spectrum Disease (NMOSD) | Dried blood spot diagnostics in Neuromyelitis Optica Spectrum Disease (NMOSD). Felix Wohlrab
15:50-16:10 Rheumatoid Arthritis | A proteomic signature predicts flare and sustained drug-free remission in seropositive rheumatoid arthritis, Jasmine Sim
16:10-16:30 Expert Panel Discussion & Audience Q&A | A moderated discussion exploring common biological pathways, emerging biomarker opportunities, and future directions for IMID research.
CSO
Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.
CFO
Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.